Clinical Dilemmas in Inflammatory Bowel Disease

Peter Irving, Centre for Gastroenterology, Institute of Cell and Molecular Science, Barts and the London, Queen Mary School of Medicine and Dentistry, London, UK. David Rampton, Professor of Clinical Gastroenterology at the Centre for Gastroenterology, Institute of Cell and Molecular Science, Barts and the London, Queen Mary School of Medicine and Dentistry, London, UK. Fergus Shanahan, Professor and Chair of the Department of Medicine, National University of Ireland Cork, Cork University Hospital, Cork, Eire.

List of Contributors. Preface. Part 1 Investigating IBD in the 21st Century. 1 Capsule endoscopy: do we need it (Joel E D Mawdsley & Mark Appleyard). 2 Pathology reports - pitfalls for the unwary (Wilfred Weinstein). 3 Non-invasive diagnosis and assessment (Alex J Di Mambro, Ana Terlevich & Chris Probert). 4 What is the best way to image perianal Crohn's disease (Vikram A Sahni & Alison McLean). 5 Surveillance colonoscopy in UC: alternatives and ways to improve outcome (Mark Lust & William Connell). 6 Abnormal liver tests - what should we do about them (Richard Marley & Abid Suddle). Part 2 Medical Treatment: Making the Most of What We've Got. 5-ASA drugs. 7 Is monitoring necessary (Rakesh Shah & Alastair Forbes). 8 Do they have a role in Crohn's disease (Vikrant Sibartie & Brian Feagan). Steroids. 9 Steroids in Crohn's: are they obsolete (David Rampton). Antibiotics for Crohn's disease. 10 Antibiotics: which, when and for how long (Alex Kent & Jean-Frederic Colombel). 11 Mycobacterium avium paratuberculosis in Crohn's disease: player or spectator (Geoff Smith & Fergus Shanahan). Immunomodulators. 12 TPMT testing: is it essential (Azhar Ansari & Jeremy D Sanderson). 13 6-Mercaptopurine or azathioprine (Dermot McGovern & Simon Travis). 14 Thiopurines: how long should we use them for (Alexandra Daley & Marc Lemann). 15 Making the most of methotrexate (Emma Greig, John Keohane & Brian Feagan). 16 Cyclosporine: balancing risk and benefit (Helena Deeney & Barney Hawthorne). Infliximab. 17 Contraindications - absolute or relative (Rakesh Chaudhary & Subrata Ghosh). 18 How can we prevent tuberculosis (Sasha Beresford & David Rampton). 19 Dealing with infusion reactions (Gert Van Assche, Severine Vermeire & Paul Rutgeerts). 20 Use in ulcerative colitis (Sreedhar Subramanian & Jonathan Rhodes). 21 Infliximab and surgery: health or hazard (David Rampton). Nutritional therapy for Crohn's disease. 22 Nutritional therapy for Crohn's disease: is it for adults (Donald R Duerksen & Charles N Bernstein). Part 3 Medical Treatment: What's Round the Corner?. 23 Trials and tribulations - interpreting clinical trials in IBD (Elizabeth Carty & David Rampton). 24 Genetics - clinical and therapeutic applications (Mark Tremelling & Miles Parkes). 25 Probiotics - separating science from snakeoil (Fergus Shanahan & John Keohane). 26 Worms (David Grunkemeier & R Balfour Sartor). 27 Smoking and nicotine - poison for Crohn's, potion for colitis (Brian Bressler & A Hillary Steinhart). 28 Heparin (Ailsa Hart & Stuart Bloom). 29 Leukocytapheresis: filtering out the facts (Peter Irving & David Rampton). 30 Appendectomy for ulcerative colitis - a therapeutic option (Richard Makins & Graham Radford-Smith). 31 Biologic treatments in IBD (Raymond D'Souza & James Lindsay). 32 Stem cell transplantation for IBD (Paul Fortun & Christopher Hawkey). 33 Complementary and alternative therapy - the way forward or a step back (Louise Langmead & David Rampton). Part 4 Common Clinical Challenges: Beyond the Text Book. 34 Functional problems (Eamonn Quigley). 35 Psychological stress: something to worry about (Joel E D Mawdsley & David Rampton). 36 Drugs to avoid (Paul Collins & Jonathan Rhodes). 37 NSAIDs and COX-2 selective agents: cause or cure of pain in IBD (Ingvar Bjarnason & David Scott). 38 Iron replacement - is it safe and effective (Stefanie Kulnigg & Christoph Gasche). 39 Hepatitis B and C viruses - how do they affect management of IBD (Graham R Foster & Alick N S Nkhoma). 40 Pregnancy: what drugs can we use (Thea Thomas & Elspeth Alstead). 41 How to prevent growth failure in children (Jutta Koglmeier & Nick Croft). 42 Predicting outcomes in severe UC. . Simon Travis. 43 Refractory proctitis (Anne Ballinger & Richard Makins). 44 CMV co-infection - does it matter (Daan Hommes). 45 Treatment of oral Crohn's disease (Carlo Nunes, Michael Escudier & Jeremy D Sanderson). 46 Pathophysiologic approach to treatment of diarrhea in Crohn's disease (Henry J Binder). 47 Short bowel (Jeremy Nightingale). 48 Management of internal fistulae (David Rampton). 49 What is indeterminate colitis (Garret Cullen & Diarmuid O'Donoghue). 50 Pouches for indeterminate colitis (Laura Hancock & Neil Mortensen). 51 Colitis-associated cancer: what's the risk to your patients (Jayne Eaden). 52 What to do with dysplasia, DALMs, and adenomas (Matt Rutter). Part 5 Managing IBD Outside the Gut. 53 Pyoderma gangrenosum (Ana Paula Cunha & Fernando Tavarela Veloso). 54 Arthritides - helping the joints without harming the gut (Horace Williams & Tim Orchard). 55 Prevention and treatment of osteoporosis (Richard Makins & Juliet Compston ). 56 Sclerosing cholangitis - what to do (Sue Cullen & Roger Chapman). 57 Thromboembolic disease: an under-recognized complication (Peter Irving & Fergus Shanahan). 58 Pulmonary manifestations: rare but real (Peter Irving). Part 6 Are You Sure it's IBD?. 59 Intestinal infections: mimics and precipitants of relapse (Sunil Samuel & Yashwant Mahida). 60 Microscopic colitis (Debbie Nathan & Peter Gibson). 61 Diverticular colitis (Linmarie Ludeman & Neil A Shepherd). Part 7 The IBD Service: Time for a Rethink?. 62 Outpatient services - do doctors still have a role (Mark Kelly & Andrew Robinson). 63 Shared care: tactical team selection (Reshma C Rakshit & John Mayberry). 64 Databases - are they worth the bother (Stephen L Grainger). Index